Stay updated on Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page.

Latest updates to the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedAdded a Locations section showing Illinois as a study site and updated to revision v3.3.3. Removed the HHS Vulnerability Disclosure and Illinois Locations entries (revision v3.3.2).SummaryDifference0.2%

- Check27 days agoNo Change Detected
- Check48 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2. This is a minor metadata change with no impact on study content or user actions.SummaryDifference0.1%

- Check55 days agoChange DetectedThe government funding and operating status notice was removed from the page, while study details remained unchanged; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check70 days agoChange DetectedOnly minor formatting and textual adjustments were observed; the core study information remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check98 days agoChange DetectedMajor update: announces a version upgrade to v3.2.0 and publicly states funding-related operational notices, including that transactions may not be processed until appropriations are enacted.SummaryDifference3%

- Check105 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rucaparib and Nivolumab in Prostate or Endometrial Cancer Clinical Trial page.